Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient ServicesMs. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025
Krystal Biotech Inc. (NASDAQ: KRYS) is a Leading Gainer in 2/26 Morning TradingKrystal Biotech, Inc. (
NASDAQ: KRYS) is one of today’s top gainers. The company’s shares have moved 35.6% on the day to $150.96.
Arbutus Appoints Two New ExecutivesKaren Sims, MD, PhD Promoted to Chief Medical Officer
Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8Krystal Biotech, Inc. (
NASDAQ: KRYS) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 0.59% on the day to $128.12.
Krystal Clear: Krystal Biotech Clears Resistance in Good VolumeRegulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem.
Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price ActionKrystal Biotech, Inc. (
NASDAQ: KRYS) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 15.72% on the day to $111.16.
